荧光原位杂交试验预测原发性高级别非肌层浸润性膀胱癌卡介苗治疗后复发和/或疾病进展的评估:前瞻性多中心试验结果
前瞻性多中心诊断试验纳入150例拟接受卡介苗治疗的原发性高级别非肌层浸润性膀胱癌患者,在首次灌注前、第六次灌注前及3个月膀胱镜检查时行UroVysion荧光原位杂交检测,评估其预测复发或进展的性能。9个月随访共46个事件(37例复发、9例进展),阳性结果与事件风险升高相关,基线HR 2.59(95%CI 1.42-4.73)、6周HR 1.94(95%CI 1.04-3.59)、3个月HR 3.22(95%CI 1.65-6.27)。
要点
- 阳性UroVysion荧光原位杂交结果与复发风险约增加3.3倍相关。
- 该检测或有助于对诱导治疗失败的临床试验入组患者进行风险分层。
- 因结果与结局不一致及检测结果随时间变异,用该检测改变管理决策受限。
核心结论
- 研究验证了阳性UroVysion荧光原位杂交检测与复发风险约增加3.3倍相关。
- 该检测或有助于对进入临床试验且诱导治疗失败的患者进行风险分层。
- 由于结果与结局不一致以及检测结果随时间变异,使用该检测改变管理决策受到限制。
研究设计与样本
- 前瞻性多中心诊断试验,共150例患者纳入分析,包括Ta期68例、T1期41例、单纯原位癌26例及乳头状癌加原位癌15例。
- 荧光原位杂交检测在首次卡介苗灌注前、第六次灌注前及3个月膀胱镜检查时进行。
主要发现
- 9个月随访期间共46个事件,包括37例复发和9例进展。
- 阳性荧光原位杂交结果对应事件的HR:基线检测为2.59(95%CI 1.42-4.73),6周检测为1.94(95%CI 1.04-3.59),3个月检测为3.22(95%CI 1.65-6.27)。
- 基线、6周和3个月结果均为阳性的患者发生事件的比例为55%,各时间点结果均为阴性的患者无事件的比例为76%。
局限性
- 原文指出检测结果与结局之间存在不一致。
- 原文指出检测结果随时间存在变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Single center studies have shown that positive UroVysion® fluorescence in situ hybridization results were associated with recurrence of nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. Our goal was to validate these findings. MATERIALS AND METHODS: We performed a prospective, multicenter diagnostic trial to determine whether the fluorescence in situ hybridization test could predict recurrence or progression in patients with primary high grade nonmuscle invasive bladder cancer who were scheduled to receive bacillus Calmette-Guérin. Fluorescence in situ hybridization testing was performed prior to the first bacillus Calmette-Guérin instillation, prior to the sixth instillation and at 3-month cystoscopy. The performance of fluorescence in situ hybridization was evaluated. RESULTS: A total of 150 patients were enrolled in analysis, including 68 with Ta disease, 41 with T1 disease, 26 with carcinoma in situ alone and 15 with papillary carcinoma plus carcinoma in situ. At 9 months of followup there were 46 events, including 37 recurrences and 9 progressions. For events with positive fluorescence in situ hybridization findings the HR was 2.59 (95% CI 1.42-4.73) for the baseline test, 1.94 (95% CI 1.04-3.59) for the 6-week test and 3.22 (95% CI 1.65-6.27) at 3 months. Patients with positive results at baseline, 6 weeks and 3 months had events 55% of the time and patients with negative results at each time point had no event 76% of the time. CONCLUSIONS: The study validated that a positive UroVysion fluorescence in situ hybridization test was associated with a 3.3-fold increased risk of recurrence. The test may be useful to risk stratify patients entering clinical trials in whom induction therapy fails. However, using the test to change management decisions is limited due to the discordance between results and outcomes as well as the variance of tests results with time.
引用
- Lotan Y, Inman BA, Davis LG, et al. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. J Urol. 2019. PMID: 31120373. doi:10.1097/JU.0000000000000355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。